Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Divided On These Sliding Stocks

Page 1 of 2

Today has not started particularly well for Rite Aid Corporation (NYSE:RAD), with the stock opening 5.64% lower after the company’s quarterly report brought disappointing news, while Peabody Energy Corporation (NYSE:BTU) has dipped into the red following some somber news of its own: that the company’s board has approved a reverse stock-split owing to its precipitous decline this year. Peabody Energy’s shares are down by over 81% year-to-date.

Best Summer Jobs for 16 Year Olds

Rite Aid’s profits for its fiscal second quarter of 2016 suffered from losses on debt retirement and increases in depreciation expenses and capital spending following the takeover of EnvisionRx. Revenues rose by 18% year-over-year to $7.7 billion, beating estimates of $7.6 billion, while earnings per share plummeted to $0.02 from the $0.13 per share registered for the same period of last year. The stock has continued to slide by more than 10% during the first hours of trading.

Rite Aid Corporation (NYSE:RAD) cut its profit guidance for the full year to a range of $0.12-to-$0.19 and reiterated revenues expectations of $30.8 billion to $31.1 billion. One of the largest drug-store chains in the United States, Rite Aid has recently bolstered its portfolio through the addition of EnvisionRx, a pharmacy benefit management company. The acquisition cost Rite Aid roughly $2 billion, paying 90% in cash and the remaining in stock (approximately 28 million shares). Rite Aid has stated that the acquisition of EnvisionRx has already had an impact on the company’s bottom line, with same-store sales increasing by 2.8% during the reported fiscal quarter.

Some hedge fund managers that we follow chose to close their positions in Rite Aid Corporation (NYSE:RAD) during the second quarter, with the total number of hedge funds holding the stock falling to 55 from 59, while the overall value of their holdings fell to $972 million from $1.15 billion. Among the hedge fund managers that we track, Larry Robbins is the biggest fan of Rite Aid, having reported a position of 12.5 million shares as of the end of the second quarter. Having initiated this position during the first three months of 2015, Robbins reduced it by approximately 11% in the second quarter. John Burbank, on the other hand, saw fit to step up his interest in the company, having increased his holding by 178% during the second quarter. His fund, Passport Capital reported ownership of roughly 11.5 million shares in its latest 13F filing. Bank of America/Merrill Lynch initiated coverage of the stock in August, assigning a ‘Buy’ rating.

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning 118% and beating the market by more than 60 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise (while avoiding their high fees at the same time) rather than large-cap stocks.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!